A Phase 1, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Safety, Tolerability, and Systemic Absorption of Menadione Topical Lotion as an Emergent and Pre-emergent Treatment for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash

Trial Profile

A Phase 1, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Safety, Tolerability, and Systemic Absorption of Menadione Topical Lotion as an Emergent and Pre-emergent Treatment for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs Menadione (Primary)
  • Indications Exanthema
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 16 Oct 2017 Planned End Date changed from 1 Dec 2015 to 1 Dec 2018.
    • 16 Oct 2017 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2018.
    • 07 Jun 2017 The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years. Last Verified in June 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top